Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Among over 125,000 patients, 53.6% discontinued their GLP-1 receptor agonist by 1 year, and these rates were significantly ...

These compounds take a different approach to weight loss than existing medications, which can cause nausea, vomiting and ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

医脉通编译整理，未经授权请勿转载。 肥胖是一种复杂的慢性疾病，全球患病率不断上升。预计到2025年，全球将有12亿人受到肥胖（BMI≥30 kg/m²）的影响。性别在肥胖及相关并发症的发病机制中存在显著差异，例如女性的肥胖患病率通常高于男性，且女性在接受药物减重干预时往往比男性获得更显著的体重减轻效果。 近年来，胰高血糖素样肽-1（GLP-1）受体激动剂被广泛用于肥胖治疗，并取得了良好的效果。Su ...

Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...

A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's ...

研究表明，GLP - 1RA 的使用与 43 种疾病风险约 10% - 20% 的降低存在关联。这些疾病涵盖了多种物质相关障碍、神经认知障碍、精神健康疾病、心血管事件、肾脏疾病、呼吸系统疾病以及细菌感染等。

近年来，随着司美格鲁肽（semaglutide）和tirzepatide相继获批用于治疗2型糖尿病（T2D）和肥胖症，胰高血糖素样肽1受体激动剂（GLP-1RA）类药物迅速引发了行业关注。近日， 来自华盛顿大学医学院的科学家在《自然》子刊 Nature Medicine ...

The study of more than two million veterans with diabetes details GLP-1 RA use relating to 175 outcomes; without ...

Recent study held under Dr. Ziyada Al-Aly found that GLP-1 medications can reduce the risk of disease like heart disease and ...